My father is 70 and he is fighting is second colorectal cancer. The
first one was surgically removed 2-3 years ago, but a second tumor
rapidly appeared. He has gone through radiotherapy and chemiotherapy
for the past 18 months or so, and he has a tumor which doctors cannot
remove because it is "too invasive" and the operation would likely
kill him. Chemiotherapy has apparently reduced slightly the size of
the tumor, but it still cannot be removed surgically. Doctors
continue to provide him with "short" chemiotherapy sessions (6-8
weeks) with scans and blood samples in-between, but they never made
any statement about a possible outlook. Sure, it is not a an exact
science. Nevertheless I don't expect him to go through chemiotherapy
for another 10 years.

I tried to find statistics about the life expectancy of someone with a
"non-removable" colon tumor (whatever what stage this is, we've never
been told) but could not find anything on the subject. If anyone has
links to point to or similar stories, please let me know. thanks.

Paul

My father is 70 and he is fighting is second colorectal cancer. The
first one was surgically removed 2-3 years ago, but a second tumor
rapidly appeared. He has gone through radiotherapy and chemiotherapy
for the past 18 months or so, and he has a tumor which doctors cannot
remove because it is "too invasive" and the operation would likely
kill him. Chemiotherapy has apparently reduced slightly the size of
the tumor, but it still cannot be removed surgically. Doctors
continue to provide him with "short" chemiotherapy sessions (6-8
weeks) with scans and blood samples in-between, but they never made
any statement about a possible outlook. Sure, it is not a an exact
science. Nevertheless I don't expect him to go through chemiotherapy
for another 10 years.

I tried to find statistics about the life expectancy of someone with a
"non-removable" colon tumor (whatever what stage this is, we've never
been told) but could not find anything on the subject. If anyone has
links to point to or similar stories, please let me know. thanks.

paul_silverman at (no spam) mail.com> kirjoitti Wed, 30 Apr 2008 23:29:51 +0300:

My father is 70 and he is fighting is second colorectal cancer. The
first one was surgically removed 2-3 years ago, but a second tumor
rapidly appeared. He has gone through radiotherapy and chemiotherapy
for the past 18 months or so, and he has a tumor which doctors cannot
remove because it is "too invasive" and the operation would likely
kill him. Chemiotherapy has apparently reduced slightly the size of
the tumor, but it still cannot be removed surgically. Doctors
continue to provide him with "short" chemiotherapy sessions (6-8
weeks) with scans and blood samples in-between, but they never made
any statement about a possible outlook. Sure, it is not a an exact
science. Nevertheless I don't expect him to go through chemiotherapy
for another 10 years.
[...]The most interesting paper
would probably be this one: Hytrek SD, McLaughlin PJ, Lang CM et al.
Inhibition of human colon cancer by intermittent opioid receptor
blockade with naltrexone. Cancer Lett. 1996 Mar 29;101(2):159-64.
PMID: 8620464. You can find more information at
http://www.lowdosenaltrexone.org

Maija Haavisto wrote:
paul_silver... at (no spam) mail.com> kirjoitti Wed, 30 Apr 2008 23:29:51 +0300:

My father is 70 and he is fighting is second colorectal cancer.  The
first one was surgically removed 2-3 years ago, but a second tumor
rapidly appeared.  He has gone through radiotherapy and chemiotherapy
for the past 18 months or so, and he has a tumor which doctors cannot
remove because it is "too invasive" and the operation would likely
kill him.  Chemiotherapy has apparently reduced slightly the size of
the tumor, but it still cannot be removed surgically.  Doctors
continue to provide him with "short" chemiotherapy sessions (6-8
weeks) with scans and blood samples in-between, but they never made
any statement about a possible outlook.  Sure, it is not a an exact
science.  Nevertheless I don't expect him to go through chemiotherapy
for another 10 years.
[...]The most interesting paper
would probably be this one: Hytrek SD, McLaughlin PJ, Lang CM et al.
Inhibition of human colon cancer by intermittent opioid receptor
blockade with naltrexone. Cancer Lett. 1996 Mar 29;101(2):159-64.
PMID: 8620464. You can find more information at
http://www.lowdosenaltrexone.org

Don't believe everything you read. If it's been around and successful with
cancer, since 1996, there would be clinical trials and there are none for
naltrexone and cancer.
138 for oother diseases and/or conditions but NONE for cancer.
Save your money. There are multiple spammerss, on various health newsgroups,
trying to "sell" people on it.
Suspicions they're sales people. (trying to make money off desperate cancer
patients).
J- Hide quoted text -

- Show quoted text -

1: Related Articles, LinksLissoni P, Malugani F, Malysheva O, Kozlov
V, Laudon M, Conti A, Maestroni G.

Neuroimmunotherapy of untreatable metastatic solid tumors with
subcutaneous low-dose interleukin-2, melatonin and naltrexone:
modulation of interleukin-2-induced antitumor immunity by blocking the
opioid system.
Neuro Endocrinol Lett. 2002 Aug;23(4):341-4.
PMID: 12195238 [PubMed - indexed for MEDLINE]2: Related Articles,
LinksLissoni P, Malugani F, Bordin V, Conti A, Maestroni G, Tancini G.

A new neuroimmunotherapeutic strategy of subcutaneous low-dose
interleukin-2 plus the long-acting opioid antagonist naltrexone in
metastatic cancer patients progressing on interleukin-2 alone.
Neuro Endocrinol Lett. 2002 Jun;23(3):255-8.
PMID: 12080288 [PubMed - indexed for MEDLINE]3: Related Articles,
LinksLissoni P, Meregalli S, Fossati V, Barni S, Tancini G, Barigozzi
P, Frigerio F.

Radioendocrine therapy of brain tumors with the long acting opioid
antagonist naltrexone in association with radiotherapy.
Tumori. 1993 Jun 30;79(3):198-201.
PMID: 8236504 [PubMed - indexed

cmarta wrote:
1: Related Articles, LinksLissoni P, Malugani F, Malysheva O, Kozlov
V, Laudon M, Conti A, Maestroni G.

Neuroimmunotherapy of untreatable metastatic solid tumors with
subcutaneous low-dose interleukin-2, melatonin and naltrexone:
modulation of interleukin-2-induced antitumor immunity by blocking the
opioid system.
Neuro Endocrinol Lett. 2002 Aug;23(4):341-4.
PMID: 12195238 [PubMed - indexed for MEDLINE]2: Related Articles,
LinksLissoni P, Malugani F, Bordin V, Conti A, Maestroni G, Tancini G.

A new neuroimmunotherapeutic strategy of subcutaneous low-dose
interleukin-2 plus the long-acting opioid antagonist naltrexone in
metastatic cancer patients progressing on interleukin-2 alone.
Neuro Endocrinol Lett. 2002 Jun;23(3):255-8.
PMID: 12080288 [PubMed - indexed for MEDLINE]3: Related Articles,
LinksLissoni P, Meregalli S, Fossati V, Barni S, Tancini G, Barigozzi
P, Frigerio F.

Radioendocrine therapy of brain tumors with the long acting opioid
antagonist naltrexone in association with radiotherapy.
Tumori. 1993 Jun 30;79(3):198-201.
PMID: 8236504 [PubMed - indexed

And how was life expectancy affected, if at all?
J- Hide quoted text -

- Show quoted text -

A new neuroimmunotherapeutic strategy of subcutaneous low-dose
interleukin-2 plus the long-acting opioid antagonist naltrexone in
metastatic cancer patients progressing on interleukin-2 alone.Lissoni
P, Malugani F, Bordin V, Conti A, Maestroni G, Tancini G.
Division of Radiation Oncology, S. Gerardo Hospital, Monza, Milan,
Italy.

OBJECTIVES: Recent advances in knowledge of Psychoneuroimmunology have
shown that several neuroactive substances, including neurohormones and
neuropeptides, may exert immunomodulatory effects. However, despite
the great variety of potential neuroimmune interactions, at present we
may recognize two major neuroendocrine systems exerting a
physiological neuroimmunomodulatory function, consisting of the pineal
gland and the brain opioid system, provided by immunostimulatory and
immunosuppressive effects, respectively. Recent in human studies have
demonstrated the possibility to amplify the biological activity of
IL-2, the major anticancer cytokine, by pineal indoles. MATERIALS &
METHODS: The present study was carried out to draw some preliminary in
human results on the possible immunomodulatory effects of the
inhibition of the brain opioid activity by a long-acting opioid
antagonist, naltrexone (NTX). The study was performed in 10 metastatic
renal cell cancer patients, who had progressed on a previous
immunotherapeutic cycle with IL-2 alone. Patients were treated with
the same doses of IL-2 (6 million lU/day subcutaneously for 6 days/
week for 4 weeks) plus an oral administration of NTX at a dose of 100
mg every 2 days. RESULTS: The clinical response consisted of a partial
response in 1 and a stable disease in 5 patients, whereas the other 4
patients progressed. Therefore, the percent of non-progressive disease
was 6/10 (60%). Moreover, mean lymphocyte increase achieved during
IL-2 plus NTX was significantly higher (P<0.05) than that obtained
during the previous treatment with IL-2 alone. CONCLUSIONS: This study
shows that a blockade of the brain opioid system, which plays a
physiological immunosuppressive role, may improve the anticancer
effects of IL-2 in humans.

PMID: 12080288 [PubMed - indexed for MEDLINE]